| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Department of Obstetrics and Gynecology [R. D. A., M. N. B.], The Gene Therapy Center [J. G-N., M. W., T. V. S., W. A., D. T. C.], Department of Pharmacology and Toxicology [M. R. J.], The Biostatistics Unit [R. B. A.], Genzyme Corporation [B. L. R.], and Departments of Pathology, Cell Biology, and Surgery [G. P. S.], The University of Alabama at Birmingham, Birmingham Alabama 35233-7333
The purpose of this Phase I study was to determine the feasibility of using an anti-erbB-2-encoding adenovirus (Ad21) to treat erbB-2-overexpressing ovarian cancer. Recurrent ovarian cancer patients were treated i.p. with Ad21 in dosages ranging from 1 x 109 to 1 x 1011 pfu. Patients were monitored after treatment for evidence of clinical toxicity and efficacy. Peritoneal aspirates and serum samples were obtained to assess for evidence of gene transfer/expression, for generation of wild-type vector, and antiadenoviral humoral response. Fifteen patients were treated per study specifications. Treatment-specific grade 1/2 fever was ex-perienced by 9 of 15 (60%) patients. Other transient grade 1/2 constitutional, pain, and gastrointestinal symptoms were also experienced. No dose-limiting vector-related toxicity was experienced. Of 13 patients evaluable for response, 5 (38%) had stable disease and 8 (61%) had evidence of progressive disease. One patient with nonmeasurable disease normalized her CA125 at the 8-week evaluation, and one patient with nonmeasurable disease remained without clinical evidence of disease for 6 months after treatment. PCR analysis of peritoneal aspirates demonstrated the presence of Ad21 in 84.6%, 84.6%, and 61.6% of evaluable specimens at days 2, 14, and 56 after treatment, respectively. No wild-type virus was detected. Reverse transcription-PCR analysis demonstrated expression of the anti-erbB-2 sFv-encoding gene in 10 of 14 evaluable patients at day 2. Five of six evaluable patients had an increase in antiadenovirus antibody titer. This study suggests that adenoviral-mediated gene therapy using an anti-erbB-2-directed intrabody is feasible in the context of human ovarian cancer.
This article has been cited by other articles:
|
|
 |
|
  J. A. McLear, D. Lebrecht, A. Messer, and W. J. Wolfgang Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease FASEB J, June 1, 2008; 22(6): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jiang, W. Shi, Q. Zhang, X. Wang, M. Guo, Z. Cui, C. Su, Q. Yang, Y. Li, J. Sham, et al. Gene Therapy Using Adenovirus-Mediated Full-length Anti-HER-2 Antibody for HER-2 Overexpression Cancers. Clin. Cancer Res., October 15, 2006; 12(20): 6179 - 6185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Paz, L. A. Brennan, M. Iacolina, J. Doody, Y. R. Hadari, and Z. Zhu Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation Mol. Cancer Ther., November 1, 2005; 4(11): 1801 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Wolfgang, T. W. Miller, J. M. Webster, J. S. Huston, L. M. Thompson, J. L. Marsh, and A. Messer Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies PNAS, August 9, 2005; 102(32): 11563 - 11568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sako, J. Kitayama, H. Koyama, H. Ueno, H. Uchida, H. Hamada, and H. Nagawa Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric Cancer Cancer Res., May 15, 2004; 64(10): 3624 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sangro, G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, et al. Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors J. Clin. Oncol., April 15, 2004; 22(8): 1389 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Korst and R. G. Crystal Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification Ann. Thorac. Surg., October 1, 2003; 76(4): 1319 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Artsaenko, K. Tessmann, M. Sack, D. Haussinger, and T. Heintges Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies J. Gen. Virol., September 1, 2003; 84(9): 2323 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Indraccolo, W. Habeler, V. Tisato, L. Stievano, E. Piovan, V. Tosello, G. Esposito, R. Wagner, K. Uberla, L. Chieco-Bianchi, et al. Gene Transfer in Ovarian Cancer Cells: A Comparison between Retroviral and Lentiviral Vectors Cancer Res., November 1, 2002; 62(21): 6099 - 6107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Canevari, S. Biocca, and M. Figini Re: Blocking Oncogenic Ras Signaling for Cancer Therapy J Natl Cancer Inst, July 3, 2002; 94(13): 1031 - 1032. [Full Text] [PDF]
|
|
|
|
|
|
A. Hemminki, K. R. Zinn, B. Liu, T. R. Chaudhuri, R. A. Desmond, B. E. Rogers, M. N. Barnes, R. D. Alvarez, and D. T. Curiel In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus J Natl Cancer Inst, May 15, 2002; 94(10): 741 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kanerva, G. V. Mikheeva, V. Krasnykh, C. J. Coolidge, J. T. Lam, P. J. Mahasreshti, S. D. Barker, M. Straughn, M. N. Barnes, R. D. Alvarez, et al. Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells Clin. Cancer Res., January 1, 2002; 8(1): 275 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
